Related Experiment Videos

Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial

J Chen1, M J Radford, Y Wang

  • 1Department of Medicine, Yale University School of Medicine, and the Yale-New Haven Hospital Center for Outcomes Research and Evaluation, Conn, USA.

Archives of Internal Medicine
|April 13, 2000
PubMed

Insights

Beta-blocker therapy after acute myocardial infarction (AMI) reduces mortality in elderly patients, including those undergoing coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA). Routine consideration of beta-blockers is recommended for revascularized AMI patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Randomized trials show beta-blockers reduce mortality post-acute myocardial infarction (AMI).
  • Many trials excluded patients undergoing coronary revascularization.
  • Clinical guidelines recommend beta-blockers for revascularized AMI patients.

Purpose of the Study:

  • To compare beta-blocker initiation at discharge in elderly AMI patients who underwent coronary artery bypass surgery (CABG) or percutaneous transluminal coronary angioplasty (PTCA) versus those who did not.
  • To examine the association between beta-blocker therapy and 1-year mortality in revascularized versus non-revascularized AMI patients.

Main Methods:

  • Utilized data from the Cooperative Cardiovascular Project.
  • Included patients aged 65 years or older hospitalized for AMI.
  • Compared beta-blocker initiation and 1-year mortality between revascularized (CABG/PTCA) and non-revascularized groups, adjusting for demographic and clinical factors.

Main Results:

  • 84,457 patients were analyzed after excluding those with beta-blocker contraindications.
  • Revascularized patients (CABG/PTCA) were less likely to initiate beta-blockers post-discharge compared to non-revascularized patients.
  • Beta-blockers were associated with significantly lower 1-year mortality in both revascularized (CABG/PTCA) and non-revascularized groups.

Conclusions:

  • Beta-blocker therapy demonstrates similar effectiveness in reducing 1-year mortality for elderly patients after AMI, regardless of whether they underwent CABG or PTCA.
  • Findings support the routine consideration of beta-blocker therapy for patients undergoing revascularization after AMI.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...